Clinical trial · no report yet · Phase 2
DEMETER
DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)
- NCT07786051 ↗
- Not yet recruiting
- The Netherlands Cancer Institute
- 19 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 7 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response - DEMETER Trial A Phase II Clinical Study to Investigate the Efficacy of Dexamethasone as an Adjunct to Endocrine Therapy in ER+, HER2- Metastatic Breast Cancer.
- Phase
- Phase 2
- Status
- Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- Dexamethasone (Oral)
- Arms
- Part 1: Dose 1 Dexamethasone + prior ET · Experimental
- Part 2: Dose 2 Dexamethasone + prior ET · Experimental
- Enrollment
- 80 (estimated)
- Primary outcomes
- Clinical Benefit Rate, which is defined as the proportion of participants having stable disease, partial response or complete response at the 16th week tumour evaluation.
- Sponsor
- The Netherlands Cancer Institute with Oncode Institute
- Start
- Nov 1, 2026 (estimated)
- Primary completion
- Nov 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07786051 · updated Aug 25, 2026